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Effect of Intravenous or Perivascular Injection of Synthetic
Adrenocorticotropic Hormone on Stimulation Test Results in Dogs
C.M. Johnson , P.H. Kass, T.A. Cohen, and E.C. Feldman
Background: Standard protocols for adrenocorticotropic hormone (ACTH) stimulation testing (ACTHst) often involve
intravenous (IV) injection of corticotropin. ACTH might be unintentionally injected into the perivascular (PV) space.
Objective: To compare stimulation test results after IV and PV injections of ACTH.
Animals: Twenty privately owned dogs were studied: 10 healthy and 10 with trilostane-treated naturally occurring hypera-
drenocorticism (HAC).
Methods: Prospective study. Each of 20 dogs underwent 2 ACTHst not <4 nor more than 14 days apart. Five
healthy and 5 HAC dogs had an IV ACTHst first and PV second; 5 healthy and 5 HAC dogs had a PV ACTHst first and
IV second. Blood samples for measurement of serum cortisol concentration were collected before and 1 hour after ACTH
administration.
Results: No significant difference in results was demonstrated when comparing serum cortisol concentrations after IV and
PV ACTH administration in all 20 dogs (median lg/dL; interval lg/dL: 8.2; 1.4–17.4 versus 7.8; 0.9–16.9; P = .23). No sig-
nificant difference in results was demonstrated when comparing serum cortisol concentrations after IV and PV ACTH admin-
istration in the 10 healthy dogs (median lg/dL; interval lg/dL: 10.9; 7.3–17.4 versus 10.6; 7.1–16.9; P = .54) or in the 10
HAC dogs (median lg/dL; interval lg/dL: 6.3; 1.4–8.6 versus 5.2; 0.9–8.7; P = .061).
Conclusions and Clinical Importance: Perivascular administration of ACTH does not significantly alter stimulation test
results in healthy dogs or in dogs with HAC undergoing therapy with trilostane.
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Serum or plasma cortisol concentrations in bloodsamples obtained before and after adreno-
corticotropic hormone (ACTH) administration are
commonly used for confirming a diagnosis of hyperadr-
enocorticism (HAC) or hypoadrenocorticism in dogs.1–5
Results of the ACTH stimulation test (ACTHst) are also
used to aid in determining optimal dose and frequency of
medications used in the short and long-term management
of dogs with HAC.4,6–8 Alpha 1–24 synthetic corti-
cotropins, potent synthetic subunits of ACTH, are com-
monly used in veterinary medicine.9,10 Several forms of
synthetic ACTH are commercially available, one is a ster-
ile lyophilized powder in vials containing 0.25 mg of
cosyntropin, which is recommended for intravenous (IV)
or intramuscular administration after it is reconstituteda
and another is a liquid synthetic ACTH product available
for IV use only.b The description of the amino acid
sequence of these 2 products is identical, and their actions
are similar.11
Cost of ACTH formulations in the USA has esca-
lated dramatically over the past several decades. Adding
the cost of ACTH to fees for obtaining the necessary
blood samples plus charges for assaying each sample
for cortisol can be considerable, causing some owners
to decline having the ACTHst performed. This concern
has led to the development of strategies to reduce the
cost of ACTHst. One approach was to dose ACTH
based on body weight as opposed to the one-large-dose-
fits-all, previously used.2,12,13 The low-dose ACTHst
provides consistent results at decreased cost.2,12,13 Other
approaches have been designed to attempt to avoid the
use of ACTHst altogether. Several groups assessed sen-
sitivity and specificity of a variety indices for confirming
a diagnosis of Addison’s disease without use of
ACTHst.5,14,15 Other groups have evaluated non-
ACTHst indices as aids in trilostane management of
dogs with HAC.16–19 Cost of ACTH is consistently
mentioned as an indication for performing such studies.
Despite alternative approaches to diagnosis and
monitoring that might avoid its use, the ACTHst
remains a “test of choice” and is the test against which
other diagnostic or monitoring protocols are often
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judged.12–19 Many veterinarians utilize the ACTHst
whenever an owner allows, because results of this test
continue to provide seemingly straightforward criteria
for making a correct decision, whether regarding diag-
nosis or assessing response to therapy. Occasionally,
however, factors such as method of restraint, venipunc-
ture technique, patient body condition, or patient tem-
perament might result in extravasation of some or of all
ACTH into the perivascular (PV) space during intended
IV administration. The effect of PV injection of ACTH
on the ACTHst is unknown.
The purpose of this study was to evaluate ACTHst
results when an entire dose of ACTH is administered
IV into the cephalic or saphenous vein, as directed on
the drug insert, compared with results obtained after an
entire dose of ACTH is injected at the same site but
into the PV space in a group of healthy dogs and in a
group of dogs being treated with trilostane for naturally
occurring HAC. This hypothesis was that ACTHst
results would be similar regardless of administration
site.
Materials and Methods
Twenty privately owned pet dogs were studied between July
2015 and July 2016. Each dog was a patient or an employee-
owned pet of the Animal Specialty and Emergency Center in Los
Angeles, CA. Informed consent was obtained from each owner
before enrollment. No dog had received glucocorticoid medication
in the 4 months preceding or during the study. No dog could be
given any new medication nor could any change in dose of trilos-
tane be made during the time period between the 2 ACTHst. Ten
healthy dogs and 10 dogs previously diagnosed as having naturally
occurring HAC were included.
The 10 healthy dogs included 6 castrated males and 4 spayed
females. Breeds represented included Cocker Spaniel (1), Labrador
retriever (1), Boxer (1), and 7 mixed breed dogs. The median age
was 6.5 years with a range of 1–14 years. Median body weight of
this population was 19.5 kg with a range of 6–43 kg. Owners of
each healthy dog believed their dog was well, each was considered
healthy on physical examination, and each had within-reference-
limit-results on CBC, serum biochemistry profile, and urinalysis.
The group of 10 dogs with HAC included 4 castrated males and 6
spayed females. Breeds represented included Akita (1), Alaskan
Malamute (1), Bichon Frise (1), Boston terrier (1), Chihuahua (1),
Jack Russell Terrier (1), Labradoodle (1), Miniature Poodle (1),
Rhodesian Ridgeback (1), and mixed breed (1). The median age
was 9.5 years with a range of 8–13 years. Median body weight of
this population was 17.4 kg with a range of 4.2–46 kg. Both the
healthy and the HAC dogs included 2 dogs each weighing 5–10,
10–15, 15–20, 20–25 and >25 kg. At the time of diagnosis, dogs
with HAC must have had clinical signs, physical examinations,
and routine biochemical findings typical for the condition. Each
dog with HAC must have had an ACTHst result or low-dose dex-
amethasone suppression test result consistent with the diagnosis.
Each of the 10 HAC dogs had been treated with trilostanec (given
with food) twice daily for at least 1 month, and each was stable
before inclusion in this study, without signs of illness aside from
those commonly associated with HAC. Median trilostane dosage
was 0.85 mg/kg, PO q12h, with a range of 0.4–2.4 mg/kg. Clinical
status and body weight did not change for any of the 20 dogs dur-
ing the interval between first and second test.
Each dog underwent 2 ACTHst, one with ACTH administered
IV and the other with ACTH given PV. All tests were conducted
using 5 lg/kg synthetic ACTHb, with volumes of ACTH adminis-
tered ranging from 0.1 to 1 mL. The second ACTHst was con-
ducted a minimum of 4 to a maximum of 14 days after the first.
All ACTHst in the healthy dogs were started between noon and
3 PM and in each HAC dog 4–6 hours after trilostane administra-
tionc. In each dog, 1 vein was used for all testing. Five healthy
dogs and 5 HAC dogs were each randomly assigned to be tested
first with the ACTH given IV: groups 1 and 3, respectively. Five
healthy and 5 HAC dogs were each randomly assigned to be tested
first with the ACTH administered into the PV space directly over
the vein: groups 2 and 4, respectively. Blood samples (2–3 mL)
were taken immediately before and 1 hour after ACTH
administration, from the same vein (saphenous or cephalic) into
which or next to which ACTH had been administered. Blood was
collected into additive-free plastic tubes, allowed to clot, spun
down, separated, and the serum frozen at 18°C until analysis.
All serum samples were assayed together after all 20 dogs had
completed both tests. The cortisol concentration in each serum
sample was determined using a validated solid phase chemilumi-
nescent immunoassay with an analytic sensitivity of 0.2 lg/dL
(5.5 nmol/L).e ,7,17,21
The study was originally powered for 20 dogs to find an effect
size of 1.0  1.5 lg/dL with a = 0.05 and ß = 0.20. The exact Wil-
coxon signed-rank test for paired data was used to evaluate the
differences in serum cortisol concentrations before and after IV
and PV administration. Analyses were performed conditional on
disease and pre/post-treatment status, as well as only conditional
on pre/post-treatment.d P-values < .05 were considered statistically
significant.
Results
The distribution of basal serum cortisol concentra-
tions before the first ACTHst in all 20 dogs (median
1.9 lg/dL; interval, 0.4–7.2 lg/dL) was not significantly
different (P = .59) from the distribution of basal serum
cortisol concentrations before the second test (median
2.4 lg/dL interval, 0.4–8.4 lg/dL; reference range: 0.5–
6.0 lg/dL). These results are consistent with the first
ACTHst having no residual effect on the second test
result. Baseline serum cortisol concentrations before IV
ACTH were merged, as were those before PV adminis-
tration. The post-IV ACTH serum cortisol concentra-
tions were merged as were the results post-PV.
The distribution of serum cortisol concentrations
before IV ACTH administration in the healthy dogs
(median 2.5 lg/dL; interval, 0.8–7.2 lg/dL) was not sig-
nificantly different (P = .63) from the distribution
before PV ACTH administration in the healthy dogs
(median 2.0 lg/dL; interval, 0.7–8.4 lg/dL). The basal
serum cortisol concentration before IV ACTH adminis-
tration in the HAC dogs (median 1.9 lg/dL; interval,
0.4–5.3 lg/dL) was not significantly different (P = .91)
from the cortisol concentration before PV ACTH
administration in the HAC dogs (median 2.6 lg/dL;
interval, 0.4–4.9 lg/dL).
The distribution of serum cortisol concentrations
after IV ACTH administration in all 20 dogs (median
8.2 lg/dL; interval, 1.4–17.4 lg/dL; reference range
6–17 lg/dL) was not significantly different (P = .23)
from the distribution obtained after PV ACTH adminis-
tration (median 7.8 lg/dL; interval, 0.9–16.9 lg/dL).
Adverse reactions were not seen in any dog during or
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after any ACTHst. The distribution of serum cortisol
concentrations after IV ACTH administration in the
healthy dogs (median 10.9 lg/dL; interval, 7.3–17.4 lg/
dL) was not significantly different (P = .54) from the
distribution of serum cortisol concentrations after PV
ACTH administration in the healthy dogs (median
10.6 lg/dL; interval, 7.1–16.9 lg/dL). The serum corti-
sol concentration after IV ACTH was higher in 4 of the
10 healthy dogs and higher after PV administration in
6. The difference in individual dogs between the post-
ACTH concentrations after IV and PV administrations
was <0.7 lg/dL in 8 of the 10 healthy dogs. In 1
healthy dog, the post-IV-ACTH serum cortisol concen-
tration was 2.1 lg/dL higher than after PV: 11.5 and
9.4 lg/dL, respectively. In 1 healthy dog, the post-IV-
ACTH serum cortisol concentration was 1.5 lg/dL
lower than after PV: 12.6 and 14.1 lg/dL, respectively.
The distribution of serum cortisol concentrations
after IV ACTH administration in the HAC dogs
(median 6.3 lg/dL; interval, 1.4–8.6 lg/dL) was not sig-
nificantly different (P = .061) from the distribution of
serum cortisol concentrations after PV administration
(median 5.2 lg/dL; interval, 0.9–8.7 lg/dL). Although
the serum cortisol concentrations after IV ACTH were
higher than after PV in 8 of the 10 HAC dogs, the dif-
ference between serum cortisol concentrations after IV
versus after PV ACTH was <1.0 lg/dL in 5 of the 10
HAC dogs. In 4 HAC dogs, the post-IV-ACTH serum
cortisol concentration was higher than after the PV
ACTH by 1.2, 1.2, 1.6, and 4.2 lg/dL, respectively. In 1
HAC dog, the post-IV-ACTH serum cortisol concentra-
tion was 1.3 lg/dL lower than after PV ACTH.
Discussion
The ACTHst is frequently used for monitoring of
HAC dogs undergoing treatment with trilostane. The
dose of trilostane may subsequently be adjusted based
on a combination of clinical signs and the more objec-
tive ACTHst results. Although both IV and intramuscu-
lar routes of ACTH administration are considered
acceptable, subcutaneous administration of ACTH has
never been evaluated so extravasation of an intended
IV injection of ACTH during the course of an ACTHst
typically results in aborting the test, or administering a
repeat dose of ACTH, incurring additional cost. Data
from all 20 dogs in this study support the reliability of
results after PV administration of ACTH. No signifi-
cant difference was found when comparing serum corti-
sol concentrations after IV and PV ACTH
administration in normal or HAC dogs, suggesting that
extravasation of ACTH is unlikely to significantly
change results. An arbitrary goal during trilostane treat-
ment is a post-ACTHst serum cortisol concentration
between 1.5 and 9.1 lg/dLc. Paired serum cortisol con-
centrations from 1 HAC dog were both <1.5 lg/dL, 8
HAC dogs had both values between 1.5 and 9.1 lg/dL,
and 1 dog had a post-IV ACTH serum cortisol concen-
tration of 2.1 lg/dL and the post-PV result in that dog
was 0.9 lg/dL. Thus, decisions regarding dose and fre-
quency of trilostane administration would not have
been different whether post-IV or post-PV results were
employed in 9 of the 10 dogs with HAC in this study.
The difference in paired post-IV and post-PV ACTHst
results in dogs with HAC was not statistically significant.
However, there was a greater discrepancy between these
values among HAC dogs than in healthy dogs. In the
healthy dogs, the difference in post-ACTHst cortisol con-
centrations in 2/10 pairs was >0.7, whereas in the HAC
dogs, the difference in post-ACTHst cortisol concentra-
tions in 7 of 10 pairs was ≥0.7 lg/dL. Eight of 10 HAC
dogs were found to have higher serum cortisol concentra-
tions after the ACTH was given IV. It is possible that
dogs with HAC are less capable of absorbing ACTH
administered PV than the healthy dogs, which could
explain these results. An alternative interpretation of
these data from dogs with HAC could be based on their
trilostane therapy. Trilostane effect on cortisol results
may be quite different, either enhanced or diminished, if
one of the paired ACTHst began as much as 1–2 hours
earlier or later than the other. It seems unlikely that
ACTHst results in healthy dogs would be affected by the
time of testing, for example, starting the ACTHst at
12:30 PM for 1 test versus 2:15 PM for the other. However,
varying the time of starting an ACTHst relative to the
time of trilostane administration by as little as 2 hours
has been demonstrated to significantly alter results.20
Thus, results from the healthy dogs in this study likely
better indicate the similarity in response to IV and PV
ACTH. Even if testing was initiated at a specific time
after trilostane administration, the systemic response to
this drug may have changed in some dogs in the 4–
14 days between tests.
If the variability found in cortisol results after PV
versus IV testing in HAC dogs in this study is indeed
related to timing of trilostane dose, then variability in
cortisol results after PV versus IV administration of
ACTH when screening dogs for HAC (not undergoing
medical therapy) may be of less concern. However, we
did not evaluate this issue nor did we study dogs with
suspected hypoadrenocorticism.
It is also relevant to note that in this study, the complete
dose of ACTH was given PV. This is in contrast to a more
realistic scenario in veterinary practice. Extravasation,
when it occurs, likely involves only a percentage of the
administered ACTH. This might indicate that in most clin-
ical scenarios, there will be even less effect on ACTHst
results. However, this is theoretical, as this study did not
evaluate such a condition. Given that a 1 lg/kg dose of
ACTH has been shown to be pharmacodynamically equiv-
alent to a 5 lg/kg dose in dogs with HAC being treated
with mitotane or trilostane,2 partial extravasation of the
5 lg/kg dose of ACTH may still cause maximal adrenocor-
tical response. Formation of a hematoma with or after PV
administration might influence effectiveness. No dog in this
study developed a hematoma.
Results of this study confirmed this hypothesis and
have shown that ACTHst results are not significantly
different when ACTH is administered PV instead of IV
in normal dogs and in dogs with HAC undergoing ther-
apy with trilostane. Based on these findings, the inad-
vertent PV administration of ACTH is unlikely to
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significantly affect results in a dog with HAC undergo-
ing a routine stimulation test. Conducting a similar
study in a larger cohort of dogs with HAC on trilostane
may more clearly address the issues studied herein.
Footnotes
a Cortrosyn, Amphastar Pharmaceuticals Inc, Rancho Cuca-
monga, CA
b Cosyntropin, Sandoz Inc, Princeton, NJ
c Vetoryl, Dechra Veterinary Products, Overland Park, KS
e Immulite 2000 cortisol assay, Siemens Healthcare Medical Solu-
tions, Los Angeles, CA
d Software: StatXact 11.0, Cytel Software Corporation, Cam-
bridge, MA
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